/Investor DB

New Leaf Venture Partners — 2019 Investments

2 investments dated 2019 · listed companies and verified rows first · show all

Passage Biopassagebio.comin𝕏NASDAQ: PASGAug 2019 · $110M

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in

BoardPatrick Heron(Director)inCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)

Co-investorsFrazier Life SciencesAccess BiotechnologyFrazier Healthcare PartnersLilly Asia VenturesOrbiMedSphera Funds Management+2 more

AiCureaicure.comin𝕏Nov 2019 · $24.5M

AICure is an AI-powered medication adherence platform for life sciences organizations that uses computer vision and machine learning to verify patient medication adherence and capture real-time behavioral data to improve clinical trial outcomes and patient engagement.

AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices

Sabina Chadha(Chief Executive Officer)inAnand Ramaswamy(Chief Product Officer)inJun Lu(VP of Engineering and AI)in

Co-investorsVIVE VCAccelmed PartnersAsahi Kasei Corporate Venture CapitalPalisades Growth CapitalSingTel Innov8 Pte Ltd.Tribeca Venture Partners+3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.